Follow
Antonio Fernandez-Nebro
Antonio Fernandez-Nebro
Professor of Rheumatology
Verified email at uma.es - Homepage
Title
Cited by
Cited by
Year
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients
R Cervera, JC Piette, J Font, MA Khamashta, Y Shoenfeld, MT Camps, ...
Arthritis & Rheumatism: Official Journal of the American College of …, 2002
25492002
Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients
R Cervera, MA Khamashta, J Font, GD Sebastiani, A Gil, P Lavilla, ...
Medicine 82 (5), 299-308, 2003
17622003
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients
R Cervera, R Serrano, GJ Pons-Estel, L Ceberio-Hualde, Y Shoenfeld, ...
Annals of the rheumatic diseases 74 (6), 1011-1018, 2015
1094*2015
Morbidity and mortality in systemic lupus erythematosus during a 5-year period: a multicenter prospective study of 1,000 patients
R Cervera, MA Khamashta, J Font, GD Sebastiani, A Gil, P Lavilla, ...
Medicine 78 (3), 167-175, 1999
5931999
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised …
PJ Mease, D van der Heijde, CT Ritchlin, M Okada, RS Cuchacovich, ...
Annals of the rheumatic diseases 76 (1), 79-87, 2017
5742017
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase …
R Fleischmann, E Mysler, S Hall, AJ Kivitz, RJ Moots, Z Luo, R DeMasi, ...
The Lancet 390 (10093), 457-468, 2017
4632017
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised …
P Nash, B Kirkham, M Okada, P Rahman, B Combe, GR Burmester, ...
The Lancet 389 (10086), 2317-2327, 2017
4382017
Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis
MD Mayes, L Bossini-Castillo, O Gorlova, JE Martin, X Zhou, WV Chen, ...
The American Journal of Human Genetics 94 (1), 47-61, 2014
2442014
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study
JL Pablos, M Galindo, L Carmona, A Lledó, M Retuerto, R Blanco, ...
Annals of the rheumatic diseases 79 (12), 1544-1549, 2020
2352020
Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double‐blind, placebo‐controlled trials
MEB Clowse, DJ Wallace, RA Furie, MA Petri, MC Pike, P Leszczyński, ...
Arthritis & rheumatology 69 (2), 362-375, 2017
2192017
Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the “Euro-Lupus Project”
R Cervera
Autoimmunity reviews 5 (3), 180-186, 2006
1872006
Osteoarticular complications of brucellosis.
JD Colmenero, JM Reguera, A Fernandez-Nebro, F Cabrera-Franquelo
Annals of the rheumatic diseases 50 (1), 23-26, 1991
1851991
A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility
FD Carmona, SL Mackie, JE Martín, JC Taylor, A Vaglio, S Eyre, ...
The American Journal of Human Genetics 96 (4), 565-580, 2015
1812015
Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus
Í Rúa-Figueroa, J López-Longo, M Galindo-Izquierdo, J Calvo-Alén, ...
Seminars in arthritis and rheumatism 47 (1), 38-45, 2017
1462017
Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists
A Fernández-Nebro, E Tomero, V Ortiz-Santamaría, MC Castro, A Olivé, ...
The American journal of medicine 118 (5), 552-556, 2005
1442005
Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review
T Cobo-Ibáñez, E Loza-Santamaría, JM Pego-Reigosa, AO Marqués, ...
Seminars in arthritis and rheumatism 44 (2), 175-185, 2014
1422014
Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study
A Fernandez-Nebro, JLM De la Fuente, L Carreno, MG Izquierdo, ...
Lupus 21 (10), 1063-1076, 2012
1352012
Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies …
M Galeazzi, G Morozzi, GD Sebastiani, F Bellisai, R Marcolongo, ...
Clinical and experimental rheumatology 16 (5), 541-546, 1998
1351998
2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis
R Sanmartí, S García-Rodríguez, JM Álvaro-Gracia, JL Andreu, A Balsa, ...
Reumatología Clínica (English Edition) 11 (5), 279-294, 2015
131*2015
Cardiovascular events in systemic lupus erythematosus: a nationwide study in Spain from the RELESSER registry
A Fernandez-Nebro, Í Rúa-Figueroa, FJ Lopez-Longo, ...
Medicine 94 (29), e1183, 2015
1272015
The system can't perform the operation now. Try again later.
Articles 1–20